*Domenico Chirchiglia, Attilio Della Torre, Pasquale Chirchiglia
Department of Neurosurgery, Neurophysiopathology Unit, University of Catanzaro, Catanzaro, Italy
*Correspondence to email@example.com
Disclosure: The authors have declared no conflicts of interest.
Received: 13.01.17 Accepted: 22.05.17
Citation: EMJ Neurol. 2017;5:88-91.
Migraine prophylaxis represents a better choice than symptomatic drugs, both for safety and for effectiveness. Today, drugs such as calcium channel blockers, beta-blockers, and topiramate are still used to treat migraine with and without aura, often with satisfactory results but in some cases with adverse effects, thus limiting their use. A new class of drugs in migraine prophylaxis are endocannabinoids, substances which modulate the mechanisms of neuroinflammation that cause migraine pain. Anandamide and palmitoylethanolamide have proven useful in migraine prophylaxis, suggesting their influence in neuroinflammatory processes and opening the way for new therapeutic perspectives.
This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
The post Focus on the Endogenous Cannabinoid System in Migraine appeared first on European Medical Journal.